HPS Pharmacies prides itself on providing innovative and informative support to assist in the diverse range of issues health professionals face on a day-to-day basis, and to facilitate the distribution of this information for a variety of sectors within the healthcare industry.
HPS’ clinical articles are written by HPS Pharmacies’ experienced and knowledgeable staff and are peer-reviewed by specialist leaders in their field to ensure the accuracy of the information provided. The resourceful and diverse range of articles play an integral role in keeping all health professionals up-to-date with the happenings throughout the industry on a regular basis.
Epilepsy is a chronic neurological disorder that affects around 250,000 Australians. Seizures occur due to sudden and disorganised electrical discharge in various parts of the brain. The clinical presentation of a seizure can vary considerably depending…
Read more
Last year Australia experienced the most severe influenza season since the 2009 pandemic year. There was some variation throughout the country, with the most significant impact seen in the eastern states. The 2017 influenza…
Read more
Osteomyelitis is an infection occurring in the bone tissue, and one can use the term for both infection of the bone marrow or infection of the bone cortex. It can be caused by spread…
Read more
Blood pressure control is paramount when it comes to managing health risks. Hypertension is known to be an important risk factor for cardiovascular diseases such as coronary artery disease, peripheral vascular disease, heart failure,…
Read more
Contact dermatitis is the most frequent occupational skin disease. It is caused by exposure to a wide range of irritants or allergens in the workplace or at home. This includes over-exposure to water, ’wet work,’…
Read more
Lonsurf® is comprised of two active ingredients: trifluridine (a nucleoside metabolic inhibitor) and tipiracil (a thymidine phosphorylase inhibitor). The tablets come in strengths expressed in milligrams of trifluridine/tipiracil: i.e. 15/6.14mg or 20/8.19mg. Currently, Lonsurf® is indicated…
Read more
